Common variant in betaine-homocysteine methyltransferase (BHMT) and risk for spina bifida

American Journal of Medical Genetics

Volumn 119 A, Issue 2, 2003, Pages 172-176

  Morin, Isabelle ^c   Platt, Robert ^c   Weisberg, Ilan ^c   Sabbaghian, Nelly ^c   Wu, Qing ^c   Garrow, Timothy A ^a   Rozen, Rima ^b  

^a UNIVERSITY OF ILLINOIS AT URBANA CHAMPAIGN   (United States)

^b RESEARCH INSTITUTE OF THE MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^c NONE

Author keywords

Betaine; Folate; Homocysteine; Polymorphism; Spina bifida

Indexed keywords

BETAINE; BETAINE HOMOCYSTEINE METHYLTRANSFERASE; FOLIC ACID; HOMOCYSTEINE; HOMOCYSTEINE METHYLTRANSFERASE; UNCLASSIFIED DRUG;

ADOLESCENT; ADULT; AMINO ACID METABOLISM; ARTICLE; BETAINE HOMOCYSTEINE METHYLTRANSFERASE GENE; CHILD; CONTROLLED STUDY; DNA MODIFICATION; DRUG BLOOD LEVEL; FEMALE; GENE; GENETIC POLYMORPHISM; GENETIC RISK; GENOTYPE; HOMOCYSTEINE BLOOD LEVEL; HOMOCYSTEINE METABOLISM; HUMAN; MAJOR CLINICAL STUDY; NEURAL TUBE DEFECT; PRIORITY JOURNAL; SPINA BIFIDA; STATISTICAL ANALYSIS;

EID: 0042322356     PISSN: 15524825     EISSN: None     Source Type: Journal    
DOI: 10.1002/ajmg.a.20115     Document Type: Article

References (21)

1. Adams MJ Jr, Khoury MJ, Scanlon KS, Stevenson RE, Knight GJ, Haddow JE, Sylvester GC, Cheek JE, Henry JP, Stabler SP, Allen RH. 1995. Elevated midtrimester serum methylmalonic acid levels as a risk factor for neural tube defects. Teratology 51:311-317.
2. Balasa VV, Gruppo RA, Glueck CJ, Stroop D, Becker A, Pillow A, Wang P. 1999. The relationship of mutations in the MTHFR, prothrombin and PAI-1 genes to plasma levels ofhomocysteine, prothrombin, and PAI-1 in children and adults. Thromb Haemost 81:739-744.
3. Botto LD, Yang Q. 2000. 5,10-methylenetetrahydrofolate reductase gene variants and congenital anomalies: A HuGe review. Am J Epidemiol 9:862-877.
4. Brown CA, McKinney KQ, Kaufman JS, Gravel RA, Rozen R. 2000. A common polymorphism in methionine synthase reductase increases risk for premature coronary artery disease. J Cardiovasc Risk 7:197-200.
5. Christensen B, Arbour L, Tran P, Leclerc D, Sabbaghian N, Platt R, Gilfix BM, Rosenblatt DS, Gravel RA, Forbes P, Rozen R. 1999. Genetic polymorphisms in methylenetetrahydrofolate reductase and methionine synthase, folate levels in red blood cells, and risk of neural tube defects. Am J Med Genet 84:151-157.
6. Cleveland WS. 1979. Robust locally weighted regression and smoothing scatterplots. JASA 74:829-836.
7. Czeizel A, Dudas I. 1992. Prevention of the first occurrence of neural tube defects by periconceptional vitamin supplementation. N Engl J Med 327:1832-1835.
8. Delvin EE, Rozen R, Merouani A, Genest J Jr, Lambert M. 2000. Influence of methylenetetrahydrofolate reductase genotype, age, vitamin B-12, and folate status on plasma homocysteine in children. Am J Clin Nutr 72: 1469-1473.
9. Fletcher O, Kessling AM. 1998. MTHFR association with arteriosclerotic vascular disease? Hum Genet 103:11-21.
10. Glavac D, Dean M, 1993. Optimization of the single strand conformation polymorphism (SSCP) technique for detection of point mutations. Hum Mutat 2:404-414.
11. Heil SG, Lievers KJ, Boers GH, Verhoef P, den Heijer M, Trijbels FJ, Blom HJ. 2000. Betainehomocysteine methyltransferase (BHMT): Genomic sequencing and relevance to hyperhomocysteinemia and vascular disease in humans. Mol Genet Metab 71:511-519.
12. Kirke PN, Molloy AM, Daly LE, Burke H, Weir DG, Scott JM. 1993. Maternal plasma folate and vitamin B12 are independent risk factors for neural tube defects. Q J Med 86:703-708.
13. Mills JL, McPartlin JM, Kirke PN, Lee YJ, Conley MR, Weir DG, Scott JM. 1995. Homocysteine metabolism in pregnancies complicated by neural-tube defects. Lancet 345:149-151.
14. MRC Vitamin Study Research Group. 1991. Prevention of neural tube defects: Results of the Medical Research Council Vitamin Study. Lancet 338:131-137.
15. Ramsbottom D, Scott JM, Molloy A, Weir DG, Kirke PN, Mills JL, Gallagher PM, Whitehead AS. 1997. Are common mutations of cystathionine β-synthase involved in the aetiology of neural tube defects? Clin Genet 51:39-42.
16. Refsum H, Ueland PM, Nygard O, Vollset SE. 1998. Homocysteine and cardiovascular disease. Annu Rev Med 49:31-62.
17. Steegers-Theunissen RP, Boers GH, Trijbels FJ, Finkelstein JD, Blom HJ, Thomas CM, Borm GF, Wouters MG, Eskes TK. 1994. Maternal hyperhomocysteinemia: A risk factor for neural-tube defects? Metabolism 43:1475-1480.
18. van der Put NM, Steegers-Theunissen RP, Frosst P, Trijbels FJ, Eskes TK, van den Heuvel LP, Mariman EC, den Heyer M, Rozen R, Blom HJ. 1995. Mutated methylenetetrahydrofolate reductase as a risk factor for spina bifida. Lancet 346:1070-1071.
19. Weisberg I, Tran P, Christensen B, Sibani S, Rozen R. 1998. A second genetic polymorphism in methylenetetrahydrofolate reductase (MTHFR) associated with decreased enzyme activity. Molec Genet Metab 64:169-172.
20. Weisberg IS, Park E, Ballman K, Berger P, Nunn M, Suh DS, Breska AP III, Garrow TA, Rozen R. Investigations of a common genetic variant in betaine-homocysteine methyltransferase (BHMT) in coronary artery disease. Atherosclerosis (in press).
21. Wilson A, Platt R, Wu Q, Leclerc D, Christensen B, Yang H, Gravel RA, Rozen R. 1999. A common variant in methionine synthase reductase combined with low cobalamin (vitamin B12) increases risk for spina bifida. Molec Genet Metab 67:317-332.